In a boost for the national efforts against the COVID-19 pandemic, the first batch of 2-deoxy-D-glucose (2-DG) drug will be launched next week, reports Livemint.
The drug has been developed by the DRDO lab, Institute of Nuclear Medicine and Allied Sciences, in collaboration with Hyderabad based pharmaceutical major Dr Reddy’s Laboratories to treat moderate to severe Covid-19 cases.
The 2-DG has been cleared by the Drug Controller General of India (DCGI) for emergency use in the treatment of Covid-19 patients earlier last week.
The first batch will comprise of 10,000 doses of 2-DG. It will be administered to patients as an adjunct therapy or an alternative treatment to assist the primary treatment.
A DRDO statement had earlier said that the clinical trial showed that the drug helps in faster recovery of hospitalized patients and reduces supplemental oxygen dependence. The patients treated with 2-DG showed faster symptomatic cure than Standard of Care (SoC) on various endpoints in the efficacy trends.
An appeal from Swarajya
At Swarajya, we rely on our readers' support through subscriptions to sustain our media platform. Unlike larger conglomerates, we are unable to relentlessly chase advertising money — our model is largely built on your patronage.
Your support has never been more crucial. We work tirelessly to deliver 10-15 high-quality articles daily, ensuring you receive insightful content from 7 AM to 10 PM.
If you believe India's story has to be articulated in a way it has never been done before without shrugging it off, become a patron (or) subscribe now for ₹̶2̶4̶0̶0̶ ₹1999 and get 12 print issues, unlimited digital access for 1 year, a special India that is Bharat T-shirt (Offer ends soon).
We are counting on you!